LSTA
Lisata Therapeutics, Inc.
Healthcare — Biotechnology
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
None
1 analysts
$1.49
+$0.05 (+3.47%)
Target:
$4.00
(168.5%)
Price History
52-Week Range
Sign in to add LSTA to a watchlist or set price alerts.
Fundamentals
| Market Cap | $30.60M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.90 |
| EPS (TTM) | $-1.86 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -91.41% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $4.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 30.2 |
| Beta | 0.81 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.07 |
| 52-Week Low | $1.81 |
| 50-Day Avg | $3.32 |
| 200-Day Avg | $3.23 |
| Avg Volume | 108.5K |
| Volume | 64.1K |
Performance Analysis
NEUTRALLSTA presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($1.81), which could present a value opportunity.
~
RSI at 30.2 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 1 analysts.
+
Average analyst target of $4.00 implies 168.5% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:19 UTC
Back to Screener Export Report